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Abstract  1 
 2 
Introduction 3 
Malnutrition is common in patients with acute kidney injury (AKI), particularly in those 4 
requiring renal replacement therapy (RRT). RRT removes metabolic waste products and 5 
toxins but it will inevitably also remove useful molecules such as micronutrients, which 6 
might aggravate malnutrition. RRT modalities vary in mechanism of solute removal e.g. 7 
intermittent hemodialysis (IHD) uses diffusion, continuous veno-venous hemofiltration 8 
(CVVH) uses convection and sustained low-efficiency diafiltration (SLEDf) uses a 9 
combination of these.  10 
Methods 11 
We assessed micronutrient and amino acid losses in 3 different RRT modalities in 12 
patients with AKI (IHD, n=27; SLEDf, n=12; CVVH, n=21) after correction for dialysis dose 13 
and plasma concentrations.  14 
Results 15 
Total losses were affected by modality, generally CVVH >> SLEDf > IHD (e.g. amino acid 16 
loss was 18.69 ± 3.04, 8.21 ± 4.07 and 5.13 ± 3.1g, respectively; P<0.001). Loss of 17 
specific trace elements (e.g. copper and zinc) during RRT was marked, with considerable 18 
heterogeneity between RRT types (e.g. +849 and +2325 µg/L lost during SLEDf vs IHD, 19 
respectively), whereas effluent losses of copper and zinc decreased during CVVH (effect 20 
size relative to IHD, -3167 and -1442 µg/L, respectively).  B-vitamins were undetectable 21 
in effluent, but experimental modelling estimated 40-60% loss within first 15 mins of RRT.  22 
Conclusion 23 
Micronutrient and amino acid losses are marked during RRT in patients with AKI, with 24 
variation between RRT modalities and micronutrients. 25 
 26 
Key words: Acute Kidney Injury, malnutrition, trace elements, amino acids, B vitamins, 27 
renal replacement therapy 28 
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Introduction 1 
 2 
Prevalence of disease related malnutrition (DRM) in AKI has been estimated at up to 3 
42% and is an independent predictor of mortality 1. Co-morbidities, prolonged hospital 4 
stay and RRT may exacerbate malnutrition. RRT may be required in AKI to remove 5 
metabolic waste products and toxins, and to regulate fluid and electrolyte balance. 6 
Inevitably, mechanisms by which RRT removes unwanted substances will also remove 7 
some essential solutes such as micronutrients and amino acids 2, 3. 8 
 9 
Many RRT modalities are now available to support patients with severe AKI. These vary 10 
in duration of treatment (intermittent to continuous) and mechanism of solute clearance 11 
(diffusion, convection or combination). These differences are likely to affect micronutrient 12 
losses. Despite high risk of DRM in patients with AKI and the huge financial burden of 13 
AKI to health services 4, little research has been published on micronutrient losses in 14 
acute RRT. We studied micronutrient losses in three RRT modalities routinely used in 15 
our renal and intensive care units: intermittent haemodialysis (IHD), sustained low 16 
efficiency diafiltration (SLEDf) and continuous veno-venous haemofiltration (CVVH). 17 
These treatments vary in duration (intermittent, intermediate and continuous, 18 
respectively) and mechanism of solute removal (diffusion (IHD), convection (CVVH) or 19 
combination (SLEDf)). Specific micronutrients and amino acids were selected for 20 
investigation based on their physiological and nutritional importance, especially in critical 21 
illness, and if their physical properties suggested removal primarily by diffusion or 22 
convection. Those fulfilling both criteria were of particular interest, such as the amino 23 
acids glutamine, arginine and taurine. Micronutrients of interest included the trace 24 
elements zinc, selenium, iron and manganese and several B-vitamins. We also wished 25 
to quantify losses of water-soluble B-vitamins: thiamine (B1), pyridoxine (B6), folic acid 26 
(B9) and cobalamin (B12). All are relatively small water-soluble molecules (B12, 1355 27 
g/mol) so extensive losses during RRT are likely. Patients requiring long term RRT for 28 
ESRD usually receive supplements containing thiamine and other water-soluble vitamins 29 
5, but the extent of losses between different  RRT modalities is not known. 30 
 31 
To describe micronutrient and amino acid losses in patients with AKI receiving different 32 
types of RRT (IHD, SLEDf and CVVH) we conducted a prospective, observational study. 33 
We hypothesised firstly that water-soluble physiologically-free molecules in plasma 34 
(including trace elements, amino acids and B-vitamins) are lost in clinically significant 35 
amounts in acute RRT and secondly that nutrient losses differ qualitatively and 36 
quantitatively between RRT modalities because of different mechanisms of solute 37 
clearance. 38 
 39 
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Methods 1 
Expanded materials and methods are available in Supplementary information. 2 
 3 
Clinical study and sampling protocol: Regional ethics committee approval and 4 
sponsorship from Nottingham University Hospitals NHS Trust were obtained. Patients 5 
with AKI were eligible for recruitment once a plan for RRT was made. Inclusion and 6 
exclusion criteria and general study sampling protocol are illustrated in Figure 6. Blood 7 
sampling: a first blood sample was taken prior to RRT commencement and plasma 8 
obtained and stored appropriately until analysis (‘base’). Further regular sampling 9 
occurred at intervals during each RRT session with the ‘mid’ or ‘end’ sample designated 10 
post-hoc as those samples taken at the mid-way or end of session (e.g. at 2 and 4h for a 11 
4h IHD treatment; at 3h and 6h for a 6h SLEDf treatment; or at 12h and 24h for a 24h 12 
CVVH treatment). The first two RRT sessions were included in the study, but if only a 13 
single session was required, no further samples were taken. Effluent sampling: Spot-14 
samples were obtained from the effluent port of each RRT machine on a schedule similar 15 
to blood sampling. ‘Baseline’ effluent was considered as the first sampled dialysate after 16 
machine priming had occurred, prior to patient attachment. For CVVH, a sample of the 17 
effluent was taken from each discarded 5L bag at 12 and 24h after commencing 18 
treatment.  19 
 20 
Analysis of free amino acids:  in plasma and effluent (490 µl) used an Amino Acid 21 
Analyser (Biochrom 20; Pharmacia LKB, Biochrom Ltd, Cambridge, UK) after 22 
deproteinization and derivatization, as described previously 6. Values for 32 amino 23 
acids were determined as μmoles/L but were mass-corrected to μg/L for absolute 24 
quantification of loss. 25 
 26 
Analysis of major and trace elements: Elemental analysis was conducted on 500 µl of 27 
plasma or effluent by inductively coupled plasma-mass spectrometry (ICP-MS; iCAPTM 28 
Q, ThermoFisher Scientific Inc., Waltham, MA, USA), as described previously 7, 8. 29 
Certified reference materials (CRMs) were included in duplicate for each ICP-MS batch 30 
run (x60-120 samples) and were SeroNormTM L-2 (REF203105, LOT0903107) and 31 
SeroNormTM L-2 (REF210705, LOT1011645; LGC, Middlesex, UK) for plasma and urine, 32 
respectively. Operational parameters were quality controlled within and between different 33 
runs. LOD, LOQ and measured values for ultrapure water, tap-water and filtrate 34 
(PrismaSol) are presented in Table 4.   35 
 36 
Analysis of B-vitamins: Effluent samples were analysed by liquid chromatography-37 
mass spectrometry (LC-MS). Chromatography was run on an Agilent 1100 fitted with 38 
Phenomenex Luna 5U C18. Mass-spectrometry used a Micromass Ultima, (Manchester, 39 
UK). Vitamin B1 (thiamine hydrochloride), B2 (riboflavin), B3 (nicotinic acid), B6 40 
(pyridoxal hydrochloride), B9 (folic acid) and B12 (cyanocobalamin) were analysed, 41 
interpolated from standard curves (0.25 to 10 ppm [0.25-10 mg/L). All B-vitamins were 42 
purchased from Sigma-Aldrich (Cheshire, UK). Parameters and conditions for 43 
chromatography and mass spectrometry are given in supplementary information.  Further 44 
information on MS conditions is given in Supplementary Table S2. 45 
 46 
Statistical Analysis: Continuous data were analysed by analysis of variance (ANOVA) 47 
or Kruskall-Wallis for skewed data and are presented as means with standard deviation 48 
- 6 - 
 
(1 SD) or standard error of the mean (1 SE) or estimated standard error of the differences 1 
between means (s.e.d.) where appropriate.  95% confidence intervals (95% C.I.) may be 2 
approximated as mean ± 2 s.e.d. Comparison of categorical or binomial data was by 3 
logistic regression and are presented as mean proportions (number [percent of total]). 4 
Comparison of treatment groups in which the data naturally followed an ordinal scale 5 
(e.g. measures of nutritional status; mild-moderate-severe) was by ordinal logistic 6 
regression. For repeated measurements, each individual was included in the model as a 7 
nested random-effect. All data are presented after correction for co-variates (e.g. dialysis 8 
dose; URR or SRI) and baseline plasma concentration. Skewed data were log10 9 
transformed to normalize residual plots. Time-series data with missing measurements 10 
were analyzed by restricted maximum likelihood (REML). More stringent P-values were 11 
assumed where multiple, potentially non-independent data were analyzed, as indicated 12 
in each Table and Figure legend. All data were analysed using Genstat v17 (VSNi, 13 
Rothampsted, UK).  14 
  15 
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Results  1 
 2 
Baseline characteristics of study population and RRT sessions  3 
We achieved 98% consent rate. The study population tended to be elderly, male with 4 
multiple co-morbidities (Table 1). Baseline patient characteristics between RRT groups 5 
were relevant to determination of co-variates for statistical models quantifying loss of 6 
micronutrients. Overall demographics were similar for the three groups (Table 1). Patients 7 
receiving RRT (CVVH) in ICU had significantly higher C-reactive peptide, consistent with 8 
the higher proportion of sepsis-associated AKI in this group (Table 1). Patients prescribed 9 
SLEDf had lower blood pressure and plasma bicarbonate than other groups (Table 2). 10 
Most patients were malnourished (Table 2) e.g. 82% were at high risk using malnutrition 11 
universal screening tool (MUST 2, a 5 step screening tool to identify adults who are 12 
malnourished, at risk of malnutrition or obese), 71% needed nutritional support according 13 
to nutritional risk screening (NRS 3; NRS contains the nutritional components of MUST 14 
as well as a disease severity grading) and 77% were at least mild-moderately 15 
malnourished according to subjective global assessment (SGA B or C; Table 2; SGA 16 
assesses 10 factors in history and examination, with classification into 3 categories of 17 
nutritional status: A=well nourished, B=moderately well nourished or at risk of 18 
malnutrition, C=severely malnourished). Details of RRT sessions are given in Table 3. 19 
Effluent volume generated per session was significantly different (IHD, 54 ± 20; SLEDf, 20 
98 ± 20; CVVH, 64 ± 21 L; P<0.001). Variation in dialysis dose (quantified by urea 21 
reduction ratio [URR] and solute removal index [SRI]), between RRT types justified 22 
inclusion of either as co-variate (blood and effluent outcomes, respectively) when 23 
analysing nutrient losses.  24 
 25 
Amino acid losses  26 
Plasma concentrations of all α-amino acids at baseline were similar for IHD and SLEDf 27 
but considerably higher for CVVH (Figure 1A). By the end of each RRT session, plasma 28 
concentration of amino acids had reduced but tended to rebound by 1-2h post-RRT (for 29 
IHD and SLED-F, CVVH for reference only; Figure 1A). This pattern was similar for all 30 
measured amino acids when considered separately but was most obvious in those 31 
present at highest concentrations in plasma (e.g. glycine and glutamine; Figure 1C & 32 
Supplementary Table 1). Minor differences in this pattern were noted for less prevalent 33 
plasma amino acids such as taurine (Figure 1E). No significant differences were noted 34 
between subgroups of amino acids (e.g. branched chain, essential or acidic groups). 35 
Corrected for plasma concentration and dose of dialysis, loss of amino acids was 36 
significantly influenced by modality (CVVH >>> SLED-F >> IHD; Figure 1B), estimated 37 
loss being similar whether sampled midway or at the end of each session. Again, the 38 
pattern of overall loss was largely driven by amino acids at highest concentration in 39 
plasma such as glutamine (Figure 1D). Nevertheless, some variation in the pattern of 40 
loss between RRT types was again noted for less abundant amino acids such as taurine 41 
(Figure 1F & Supplementary Table 1).  42 
  43 
Trace element losses  44 
Total measured plasma trace element composition was similar between RRT groups at 45 
baseline and did not change appreciably during or after the first RRT session (Figure 2A). 46 
This is likely attributable to patient heterogeneity for overall plasma trace element profile. 47 
Analysis of individual trace elements revealed some clear effects. Plasma selenium 48 
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(Figure 2B), zinc (Figure 2C) and copper (Figure 2D) were markedly higher in patients 1 
receiving IHD compared with other modalities. Duration of RRT, regardless of modality, 2 
reduced plasma caesium (pooled means; from 1.11 to 0.70 ± 0.30 µg/L; Ptime=<0.001), 3 
iron (Figure 2E), molybdenum (pooled means; from 3.79 to 2.74 ± 0.41 µg/L; Ptime=0.01) 4 
and rubidium (pooled means; from 242 to 158 ± 8.7 µg/L; Ptime=<.001) but increased 5 
plasma chromium (Figure 2F). Significant reduction in plasma concentration of trace 6 
elements by the end of an RRT session, relative to the patient’s baseline, suggests net 7 
loss from the plasma pool. Trace elements in plasma that did not vary with RRT modality 8 
or time were (all µg/L, pooled median [IQR]): Mn (1.14 [0.62-1.68]), Sr (32.8 [27.0-37.9]) 9 
and Va (1.66 [0.69-2.24]).  10 
 11 
For calculation of net effluent trace element loss attributable to RRT, mass of each 12 
element present in effluent above limits of quantification multiplied by effluent volume was 13 
considered, corrected for plasma concentration and dose of dialysis (SRI). In addition, 14 
the quantity of trace element present in effluent at baseline i.e. when sampled post-filter 15 
but prior to patient attachment, multiplied by effluent volume, was subtracted from all 16 
values. Loss of major elements (S, Ca, P, Na, Mg and K) was calculated but data are not 17 
shown because the study hypotheses did not consider these elements. In total, net losses 18 
of 13 of 32 trace elements between modalities of RRT were assessed with significance 19 
levels adjusted accordingly. For effluent zinc, no significant net loss above baseline 20 
occurred in IHD (Figure 3A), but removal as a result of SLEDf was noted (average 848 ± 21 
1032 µgs increase in effluent concentration from Base-to-End; Figure 3A).  Apparent gain 22 
of zinc (i.e. gain to patient) resulted during CVVH (i.e. net decrease in effluent Zn from 23 
Base-to-End; Figure 3A).  A statistically significant loss of strontium occurred with all 24 
modalities of RRT (Figure 3B), with effluent levels different between modalities at 25 
baseline (P for effect of RRT mode = 0.003). The latter effect was also observed for 26 
vanadium, which was lower in effluent of CVVH patients (Figure 3E). For caesium (Figure 27 
3C) and molybdenum (Figure 3E) an effect of time only was noted. Trace elements in 28 
effluent above LOQ, but not significantly influenced by modality or duration of RRT were: 29 
Cr, Cu, Fe, Mn and Se (Figure 3E). In summary, net loss of trace elements to effluent as 30 
a consequence of RRT was negligible for IHD (net loss -369 ± 1094 µgs), statistically 31 
significantly higher for SLEDf (+1787 ± 1603 µgs), but negligible-to-reversed for CVVH 32 
(net loss -1099 ± 1012 µgs) (Figure 3D).  33 
 34 
B-vitamin losses 35 
Methods for simultaneous measurement of the B-vitamin series (1, 2, 3, 6, 9 and 12) 36 
were optimised to quantify losses at <10 ppb (i.e. <10 µgs/L) but no measurable values 37 
were detected in effluent for any modality at any time point (50 samples). Reasons could 38 
include (i) dilution of signal (i.e. by 50-100 L of effluent), (ii) conversion to alternative 39 
metabolites not discriminated on targeted mass spectrometry (e.g. thiamine 40 
pyrophosphate is main form of Vit B1 [Mwt; 425.31 g/mol], but thiamine mono/tri-41 
phosphate and adenosine thiamine diphosphate are other active forms [Mwt; 345.33 and 42 
674.5, respectively]) or (iii) they are not removed to effluent by RRT. The last is unlikely 43 
as the filtration coefficient for micromolecules 1000 Kd is ~1.0 and Vit B12, the largest 44 
B-vitamin, has Mwt of 1355 g/mol. Adsorption to the RRT circuit and dialyser/filter is a 45 
possible explanation. This would represent net loss to the patient but would not appear 46 
in effluent. We therefore generated preliminary data using an in vitro model of RRT (using 47 
HDF440 filter for CVVH) with supraphysiological levels of B-vitamins added to 48 
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replacement solution (Prismasol for CVVH) to demonstrate net filtration and adsorption 1 
(Supplementary Figure S1A,B). After only 5 minutes of pseudo-filtration, there was a 2 
marked difference in B-vitamin concentration of replacement solution and effluent, 3 
accountable only by adsorption to the circuit and/or filter (Figure S1A,B). Similar results 4 
were obtained for trace elements (Figure S1C) and amino acids (Figure S1D). However, 5 
elution of used dialysers and filters with an acidified ethanol solution (after rinsing and 6 
clearance of blood; Figure S1E) recovered only minimal (<1g for all modes of RRT) 7 
quantities of amino acids (Figure S1F). 8 
 9 
First vs second session of RRT 10 
Only 28 patients (IHD, n=11; SLED-F, n=3; CVVH, n=14) received a second RRT 11 
session. For those patients, variability of end-points was generally increased but pattern 12 
of micronutrient change during RRT was similar (Figures 4 and 5). For example in 13 
plasma, amino acid concentrations tended to decline during each session (Figure 4A,B) 14 
with some declining further between end of first and start of second RRT session (e.g. 15 
plasma glutamine, Figure 4C,D). Concentration of trace elements in plasma again was 16 
largely unaffected by RRT (Figure 4E,F). Effluent losses of micronutrients generally 17 
followed the pattern observed during the first session, but with lower total losses (e.g. 18 
amino acids, Figure 5A,B). This was not the case for all amino acid groups, with little 19 
apparent effect on branched-chain amino acids (isoleucine, leucine and valine; Figure 20 
5C,D). Similarly, comparison of effluent trace element loss during RRT2 between 21 
modalities followed a similar pattern to RRT1, with slightly lower losses (e.g. for zinc, 22 
Figure 5E,F). 23 
  24 
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Discussion  1 
 2 
We have confirmed high prevalence of disease-related malnutrition (DRM) in patients 3 
with AKI requiring RRT. We demonstrated that acute RRT results in significant losses of 4 
amino acids and micronutrients. Such losses may contribute to DRM. We show for the 5 
first time that these losses vary both qualitatively and quantitatively with type of RRT. 6 
These data raise the possibility that tailoring of nutritional supplements to mode of RRT 7 
might be indicated in the future, if further evidence is acquired. 8 
 9 
Loss of amino acids: three different methods of nutritional assessment were used pre-10 
RRT 9, 10. The proportion of patients at risk of malnutrition was very high, 82% in this study 11 
using MUST. Contributing factors to pre-RRT DRM in AKI patients are likely to include (i) 12 
reduced food intake, because of anorexia or malabsorption, (ii) increased catabolism 13 
associated with acute illness and sepsis, (iii) increased gastrointestinal losses. 14 
Micronutrient loss from RRT has previously been considered but, prior to the present 15 
study, none had compared three different modalities. We demonstrate marked amino 16 
acid loss for all 3 modalities, with greatest losses for CVVH (~14-22g per session), 17 
followed by SLEDf (~7-10g) then IHD (~3-6g). This difference between modalities 18 
remained, though attenuated, after adjustment for delivered dose of RRT and baseline 19 
plasma amino acid concentration (both differed considerably between RRT groups). It is 20 
likely that plasma amino acids levels were greatest in the CVVH group due to enteral or 21 
parenteral supplements 11. These data suggest that amino acids are lost more from 22 
convection-based RRT than from diffusion-based treatment. Modes of RRT using a 23 
combination of both mechanisms were predictably intermediate for amino acid loss. 24 
Previous studies have demonstrated significant amino acid loss during CVVH 12, 13 and 25 
also during haemodialysis 14, but the latter studied patients with ESRD, which has 26 
important pathophysiological differences from AKI and should not be compared directly. 27 
We suggest that nutritional assessment of patients receiving RRT might need to take into 28 
account the mechanism of solute removal. Specifically, convection-based RRT, 29 
increasingly being used in renal units, may have a greater effect on metabolism and 30 
nutritional homeostasis than diffusion-based RRT.  31 
 32 
Reductions in total serum/plasma amino acids during RRT, as observed in this study 33 
(with the exception of IHD) are common, but some ambiguity exists 14, 15. Such variability 34 
may relate to differences in the study cohorts in terms of their nutritional or metabolic 35 
state. Sampling of the plasma amino acid pool is a snap-shot of overall protein turnover 36 
(composite of protein assimilation/supplementation versus degradation). For individual 37 
amino acids, those at relatively high concentration in plasma (e.g. glutamine, glycine) 38 
tended to dominate the overall pattern of loss between modes of RRT. For some such as 39 
taurine, however, important differences were noted such as more being lost in SLEDf 40 
than CVVH (a decrease of ~30-50 µmol/L from baseline of 62 ± 45 µmol/L). Acute or 41 
chronic taurine deficiency has been associated with heart failure 16. We were particularly 42 
interested in assessing losses of essential and conditionally essential amino acids 43 
because we assumed that their deficiency might be more likely to result in adverse clinical 44 
consequences. Losses varied with mode of RRT but, for example in SLEDf, plasma 45 
concentration decreased from 821 to 545 ± 114 umol/L, illustrating the effect that RRT 46 
can have on important micronutrients that can be restored only through diet.  47 
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Loss of trace elements was variable between elements and between modes of RRT for 1 
the same element. Differing behaviours of individual elements is not surprising as they 2 
vary in size, charge, protein binding and movement between extra- and intracellular 3 
compartments. We were particularly interested in selenium, copper, zinc and iron 4 
because of their roles in immune response to critical illness and in oxidative stress 17, 5 
which is a feature of AKI 18. Small clinical and in vitro studies have demonstrated loss of 6 
trace elements in haemofiltrate 19-21. Tonelli et al suggested that marginal Se status is 7 
strongly associated with risk of death and hospitalisation, although this was a study of 8 
incident haemodialysis patients with ESRD rather than AKI 22. Compared with published 9 
reference ranges for healthy adults, baseline plasma Se, Cu and Zn levels were low in 10 
our study, again consistent with DRM in AKI and critical illness 23, 24. Zn effluent losses 11 
varied markedly between RRT modalities, with adjusted loss greatest for CVVH. Rate of 12 
loss appeared to increase with duration in SLEDf but remain unchanged for IHD. A 13 
possible explanation is that Zn is removed more by convection because this mechanism 14 
can remove larger, protein-bound, molecules to some extent. Furthermore, our in vitro 15 
data suggest that Zn adsorption could be considerable (Figure S1C) and this would 16 
remain unaccounted for in any analyses.  17 
 18 
We optimised methods to detect B-vitamins in the ppb range but were unable to detect 19 
any >LOD in effluent. We attribute this to the dilution effect of large effluent volumes. B-20 
vitamin deficiency can occur in patients with ESRD receiving regular haemodialysis. 21 
Standard practice is to prescribe supplements of water-soluble vitamins. It is not known 22 
whether clinically significant losses of water-soluble vitamins occur in RRT for AKI where 23 
patients usually undergo only a limited number of RRT sessions and are likely to have 24 
different pre-treatment pathophysiological status. We assume that significant vitamin loss 25 
does occur based upon molecular size, charge and lack of protein binding but we have 26 
been unable to quantify it. Our in vitro study, using supraphysiological but easily 27 
measurable concentrations of B vitamins added to filtrate, suggested that significant 28 
adsorption to the haemofilter occurs. Such an effect would partly explain the undetectable 29 
levels in RRT effluent. 30 
 31 
This study has several limitations. Firstly it is an observational study in which prescription 32 
and details of each RRT were determined by clinicians independent of the study. RRT 33 
modality, duration, pump speeds and delivered dose therefore varied. We could not 34 
randomise patients to RRT groups and we recruited fewest patients to the SLEDf group. 35 
Unsurprisingly the CVVH group, recruited from ICUs, had the worst baseline clinical 36 
nutritional status. Secondly we measured only plasma levels of nutrients, which may not 37 
reflect total body status of a nutrient. The volume of distribution, degree of protein binding 38 
and kinetics of transfer between fluid compartments is likely to vary between the nutrients 39 
which we studied. We have adjusted our results for plasma concentrations but we have 40 
not attempted to incorporate two-compartment kinetic modelling into our calculations. It 41 
might be that two compartment modelling would be appropriate for some individual 42 
nutrients, including those for which we noted a degree of post-RRT rebound in plasma 43 
concentration (such as glutamine). We acknowledge that comparison between RRT 44 
modalities is particularly complex for such solutes. Nevertheless we believe that we have 45 
adopted a pragmatic approach to the calculation of total nutrient losses and comparison 46 
of these losses between RRT modalities.  47 
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Another limitation was the inability to quantify enteral and parenteral input of individual 1 
nutrients, though all patients in the CVVH group received some supplementation. We 2 
provided indirect evidence for adsorption of some micronutrients from an in vitro 3 
experiment, but we were unable to quantify the extent of adsorption of amino acids, trace 4 
elements or B vitamins in the clinical study. This will be an important challenge in future 5 
studies. It will also be of interest to study differences in adsorption of micronutrients to 6 
different RRT membrane types e.g. polyacrylonitrile (a component of the AN69 7 
hemofilter) and polysulphone (a component of the FX60 dialyzer). Markedly different 8 
degrees of adsorption of specific micronutrients between membrane types might 9 
confound interpretation of the corresponding effluent concentrations. 10 
 11 
Our data derived mainly from patients receiving their first and only session of RRT. Only 12 
28/72 patients in our cohort required a second RRT session so our data may reflect 13 
qualitative and quantitative differences at this time, rather than being representative of a 14 
prolonged schedule of RRT. However, our analysis of patients receiving a second RRT 15 
session broadly corresponded to their first, with evidence for gradual nutritional depletion. 16 
The observation that less than 40% of patients required a second RRT session was 17 
perhaps surprising but was similar to data from our unit for similar years. One possible 18 
explanation would be a low threshold for initiation of RRT, which was a clinical decision 19 
independent of the study. Such an approach might increase reported renal recovery rate. 20 
It was not surprising that the highest rate of second RRT was in the CVVH group (15/24), 21 
as these were the most inwell patients. 22 
 23 
The fact that most RRT sessions in the study represented a first treatment of patients 24 
with AKI, together with the observational design with no control over RRT prescription, 25 
explains the low blood pump speed for IHD. Indeed it is similar to those for SLEDf and 26 
CVVH, though dialysate flow rates are markedly different. It would be of interest to acquire 27 
data from several consecutive RRT treatments, likely with increasing blood pump speeds, 28 
but this was not feasible within the design of this study. 29 
 30 
To our knowledge, this is the first study to compare loss of amino acids and micronutrients 31 
in IHD, SLEDf and CVVH. These 3 RRT modalities are used commonly to manage AKI 32 
and were chosen to allow comparison of mechanisms of solute clearance: diffusion, 33 
combined diffusion + convection, and convection. Even though patient numbers were 34 
small, this is one of the largest studies investigating loss of micronutrients in acute RRT, 35 
a potentially important research area so far largely neglected. The study was not 36 
designed to investigate clinical consequences of micronutrient loss, but it has provided 37 
data which will facilitate design of such studies. Further work is required to investigate 38 
the detail of individual micronutrient clearance with different RRT modalities. Thereafter, 39 
if larger studies suggest evidence of clinically significant losses and adverse clinical 40 
outcomes (or surrogates such as markers of inflammation), a future step might be to 41 
design interventional studies with bespoke nutritional supplements.  42 
 43 
In conclusion, we have demonstrated significant amino acid and trace element loss in 3 44 
RRT modalities commonly used to manage AKI. The pattern of nutrient losses varies 45 
considerably between modalities (convection >> haemodiafiltration > diffusion). The type 46 
of RRT used to manage AKI might influence the patient’s risk of malnutrition and their 47 
nutritional requirements. Far more research is required in this important area. 48 
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Supplementary Material  1 
 2 
1. Table S1: the change in plasma and effluent amino acids during RRT  3 
Table legend:  Plasma losses: Data reflect average decrease over the course of each RRT session 4 
(concentration at End minus baseline). Statistics (P-value, plasma) are for the effect of time on plasma 5 
concentration. Effluent losses: Since there was no significant difference between losses estimated at mid 6 
or end RRT session, data reflect pooled average losses (for Mid and End samples). Statistics (P-value, 7 
effluent) are for the effect of RRT on net loss in effluent. 95% confidence interval for the data may be 8 
estimated as 1.96 × s.e.d. Some α-amino acids were measureable but at limits of quantification, and 9 
unreliable (anserine, betalanine, carnosine, ethanolamine, gammaaminobutyricacid, homocysteine, 10 
hydroxylysine, phosphoserine, phosphoethanolamine, sarcosine). Key: ‘s.e.d’, standard error of the 11 
differences between means. P-value testing for effect of RRT mode only (as timepoints are pooled 12 
estimates). 13 
 14 
2. Table S2: LC-MS/MS parameters and limits of detection for B vitamins in effluent 15 
2 tables: Experimental Details: Standards were prepared for LC-MS/MS as described in Methods but 16 
briefly; 400ppm of standards, prepared as stock solution using mobile phase solvent A. These were diluted 17 
serially using mobile phase A to achieve a concentration range of 10ppm, 5ppm, 2ppm, 1ppm, 0.5ppm, 18 
0.25ppm. The folic acid stock solution was dissolved in 0.1% NaOH before serial dilution. A standard 19 
calibration curve was plotted for each vitamin. Stock vitamins were stored at -20 C. All were purchased 20 
from Sigma-Aldrich. 21 
LC conditions (Agilent 1100 series): 22 
MS conditions (MicroMass Ultima MS) 23 
 24 
3. Figure S1: an in vitro model of micronutrient adsorption to RRT circuits 25 
Figure legend: Micronutrient adsorption to RRT circuits: A; An HDF440 was primed (30mins) using 26 
standard PrismaSol solution before addition of supraphysiological concentration of B-vitamins (B), trace 27 
elements (C) and amino acids (D, all purchased from Sigma-Aldrich). Replacement solution was sampled 28 
before (Base, -5mins) and after (time zero, 0mins) addition of micronutrients and amino acids and 29 
subsequently at 5, 30 and 60mins of ‘pseudo’-RRT. Data are mean ± S.E. (standard error of the mean) of 30 
3-4 independent experiments. E, In a separate experiment n=15 spent filters (IHD & SLED-F, Fx60; CVVH, 31 
AN69) were rinsed of blood contamination (for 1-2h with PBS plus 3mM EDTA at 80mls/min) and flushed 32 
with an eluting fluid (100 mLs, 50:50 EtOH:Water + 0.1M HCl for 15mins at 80mls/min). The resulting elute 33 
(50-80mls) was evaporated to dryness before reconstitution in 1ml amino acid running buffer for 34 
measurement of adsorbed amino acids (F). 35 
 36 
4. Expanded materials and methods: 37 
 (i) clinical study 38 
 (ii) analysis of free amino acids in plasma and effluent 39 
 (iii) analysis of major and trace elements in plasma and effluent 40 
 (iv) analysis of B vitamins in effluent 41 
 (v) statistical analysis 42 
 (vi) estimation of dose of dialysis 43 
 (vii) a priori power calculation for sample size 44 
 45 
Supplementary Material available at KI Reports website 46 
 47 
  48 
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Tables 1 
Table 1. Patient characteristics at admission stratified by type of renal replacement therapy 2 
 3 
  4 
Table 1. Data are Mean  1SD for continuous variables and number of patients (% of group 5 
total) positive for each category.  *Statistical differences between groups of patients on 6 
admission were assessed by Kruskall-Wallis One-Way ANOVA for continuous variables 7 
and chi-squared test for categorical data. All data analyses were conducted using Genstat 8 
v17 (VSNi, UK).  Statistical significance was accepted at P < 0.05.  9 
  10 
Characteristic All 
(n=72) 
 IHD 
(n=33) 
SLEDf 
(n=15) 
CVVH 
(n=24) 
P-value* 
Age, yr 65  13  66  14 70  11 62  12 0.17 
Weight, kg 84.9  21.8  91.4  24.2 77.4  20.2 80.6  16.9 0.057 
BMI 26.8  6.1  27.6  6.3 25.7  7.6 26.4  4.8 0.47 
Male 54 (75)  25 (75) 10 (66) 19 (79) 0.43 
Systolic blood pressure, mm Hg 128  27  140  25 99  20 121  23 <.001 
Diastolic blood pressure, mm Hg 68  12  75  11 59  9 62  9 <.001 
Ethnicity (% Caucasian) 71 (99)  33 (100) 14 (93) 24 (100) - 
Inotropic support (%) 
inotropes) 
24 (33)  0 0 24 (100) - 
Co-Morbidities        
Septic AKI 38 (52)  10 (30) 8 (53) 20 (83) <.001 
Multiple AKI causes 25 (35)  8 (24) 6 (40) 11 (45) 0.21 
CKD 31 (43)  16 (48) 9 (60) 6 (25) 0.06 
Diabetes 35 (43)  18 (54) 8 (53) 9 (37) 0.40 
Hypertension 41 (56)  22 (66) 8 (53) 11 (45) 0.27 
Serum parameters        
Creatinine, µmol/L 575  313  692  307 592  388 404  175 <.001 
Urea, mmol/L 34.3  15.5  36.7  9.6 30.5  12.5 29.8  15.2 0.08 
Sodium, mmol/L 133  7  132  7 133  7 135  7 0.28 
Potassium, mmol/L 5.24  1.00  5.15  1.0 5.57  0.95 5.15  1.03 0.25 
 Bicarbonate, mmol/L 17.8  5.9  17.7  5.5 14.8  5.7 19.9  5.9 0.019 
Phosphate, mmol/L 2.37  1.05  2.56  1.02 2.59  1.19 1.99  0.96 0.08 
Albumin, g/L 22.5  7.7  23.8  6.9 22.8  8.9 20.4  7.8 0.21 
C-reactive peptide, mg/L 140  118  114  112 112  99 196  122 0.01 
- 18 - 
 
Table 2. Nutritional Status of Study Participants stratified by type of renal replacement 1 
therapy 2 
 3 
 4 
Table 2. Values are Mean  1SD for continuous data and number (% of group total) for categorical 5 
data.  *Statistical differences between groups of patients on admission were assessed by Kruskall-6 
Wallis One-Way ANOVA for continuous data and chi-squared test for categories of nutritional 7 
assessment tools. All data analyses were conducted using Genstat v17 (VSNi, UK).  Statistical 8 
significance was accepted at P < 0.05. Key: Subjective Global Assessment (SGA) tool assessed 9 
using a 7-point scale: A (6-7) = well nourished, SGA B (3-5) = mild-moderately malnourished, SGA 10 
C (1-2) = severely malnourished; Malnutrition Universal Screening Tool (MUST) on a 3-point scale: 11 
MUST 0 = low risk, MUST 1 = medium risk, MUST 2 = high risk of malnutrition; Nutritional Risk 12 
Screening (NRS) was assessed using a 6-point scale with 2 points = nutritional support not 13 
indicated and NRS 3 = nutritional support indicated. 14 
  15 
Characteristic All 
(n=73) 
 IHD 
(n=33) 
SLEDf 
(n=15) 
CVVH 
(n=24) 
P-value* 
Dietetic assessment        
MUST 0 11 (15)  7 (21) 2 (13)  2 (8) 0.06 
1 2 (3)  2 (6) 0 (0)  0 (0) - 
2 60 (82)  25 (73) 13 (87)  22 (92) 0.13 
NRS 2 21 (29)  16 (47) 2 (13)  3 (12) <0.001 
NRS 3 52 (71)  18 (53) 13 (87)  21 (88) 0.55 
SGA A 17 (23)  10 (29) 3 (20) 4 (17) 0.09 
B 36 (49)  20 (59) 7 (47) 9 (38) 0.03 
C 20 (28)  4 (12) 5 (33) 11 (46) 0.21 
Serum parameters        
Plasma glucose, mmol/L 6.97  3.58  7.13  3.87 7.54  4.02 6.55  3.06 0.78 
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Table 3. RRT characteristics of study participants  1 
 2 
 3 
Table 3. Values are Mean  1SD for continuous data and number (% of group total) for categorical 4 
data. Only a proportion of study participants received a second RRT session (IHD, n=11, SLED-F, 5 
n=4, CVVH, n=15) in this cohort. Hence information is included for comparison (to first session, T1) 6 
but was not formally compared. For T1, *statistical differences were assessed by Kruskall-Wallis 7 
One-Way ANOVA for continuous data. All data analyses were conducted using Genstat v17 (VSNi, 8 
UK).  †, fixed filtration fluid rate (mls/kg min-1) 9 
  10 
Characteristic  IHD 
(n=33) 
SLEDf 
(n=15) 
CVVH 
(n=24) 
P-value* 
RRT (First session, T1)      
Prescribed RRT time, mins  120  5 344  42 1440  0 - 
Actual RRT time, mins  122  22 282  105 1225  341 - 
Blood flow rate, ml/min  207  17 214  29 234  25 <.001 
Plasma flow rate, ml/min  145  13 148  21 169  25 <.001 
Effluent flow rate, ml/min  462  121 209  26 †35  0 - 
Serum urea pre-RRT, mmol/L  36.7  9.6 35.9  24.1 29.8  15.2 0.03 
Serum urea post-RRT , mmol/L  28.5  8.4 22.7  24.3 18.7  9.0 <.001 
Urea reduction ratio (URR)  0.31  0.14 0.54  0.18 0.38  0.16 <.001 
Kt/v  0.41  0.21 0.94  0.42 0.85  0.41 <.001 
Solute removal index (SRI)  0.28  0.14 0.45  0.51 0.51  0.21 <.001 
RRT (Second session, T2)  (n=11) (n=4) (n=15)  
Prescribed RRT time, mins  180  26 360  0 1440  0 - 
Actual RRT time, mins  185  30 323  56 1244  319 - 
Blood flow rate, ml/min  225  25 203  5 234  28 - 
Plasma flow rate, ml/min  159  24 140  7 140  58 - 
Effluent flow rate, ml/min  516  65 200  0 †35  0 - 
Serum urea pre-RRT, mmol/L  25.8  11.6 25.8  19.5 13.6  5.1 - 
Serum urea post-RRT , mmol/L  15.7  8.0 10.0  6.4 10.1  4.1 - 
Urea reduction ratio (URR)  0.17  0.09 0.35  0.17 0.38  0.16 - 
Kt/v  0.21  0.11 0.51  0.25 0.83  0.34 - 
Solute removal index (SRI)  0.40  0.11 0.26  0.01 1.40  0.93 - 
- 20 - 
 
Table 4. Limits of detection, quantification and baseline reference samples for ICP-MS 1 
 2 
Major element  
(ppm, mg L-1) 
CRM Seronorm 
L2 Plasma 
(% recovery) 
CRM Seronorm  
L2 Urine 
(% recovery) 
LOD 
(ppb) 
 
LOQ 
(ppb) 
Ultrapure 
Water 
(18 MΩ cm) 
Tap 
Water 
Filtration 
fluid 
(PrismaSol) 
Sulphur 1335 (105) 671 (101) 8.5 21.3 13.41±0.93 37.4±2.14 <LOQ 
Calcium 119 (102) 119 (94) 0.08 0.20 <LOD 52.0±1.54 48.5±4.4 
Phosphorus 110 (113) 807 (102) 0.08 0.22 <LOD 0.95±0.11 <LOQ 
Sodium 3531 (102) 2815 (89) 0.08 0.21 0.88±0.45 35.8±1.90 2804±165 
Magnesium 33.9 (96) 78 (89) 0.02 0.05 0.04±0.00 10.4±0.54 13.8±1.3 
Potassium 221 (104) 1921 (92) 0.09 0.22 0.48±0.07 6.76±0.34 127±13 
Trace element (ppb, µg L-1)        
Zinc 1532 (115) 1281 (104) 11.0 27.5 1.9±0.19 489±273 94.8±27.8 
Iron 2150 (95) 13.9 (147) 0.70 1.76 9.83±2.7 17.7±2.5 15.0±5.5 
Copper 1925 (91) 56.3 (108) 0.12 0.29 1.53±0.22 100±32 4.5±2.5 
Manganese 14.5 (106) 9.3 (109) 0.09 0.23 2.12±0.79 1.12±0.15 <LOD 
Strontium 110 (107) 120 (97) 0.09 0.22 0.45±0.11 247±2 22.4±2.0 
Selenium 136 (106) 71.7 (117) 0.34 0.86 0.79±0.41 10.0±3.4 2.0±0.5 
Chromium 5.7 (101) 30.1 (95) 0.15 0.39 <LOD <LOD <LOD 
Vanadium 1.1 (149) 26 (99) 0.05 0.13 <LOD <LOD 0.68±0.06 
Molybdenum 1.21 (149) 48 (92) 0.21 0.52 <LOD <LOD <LOQ 
Rubidium 8.7 (109) 1150 (113) 0.10 0.25 0.20±0.02 4.95±0.65 <LOQ 
Lithium 9689 (116) 100 (98) 0.05 0.13 <LOD 7.27±0.58 <LOQ 
Caesium 0.02 (233) 6.6 (110) 0.02 0.05 <LOD 0.15±0.00 <LOD 
Table 4: Certified reference materials (CRM) were obtained from LGC Standards, Bury, UK. 3 
Limits of detection (LOD) and quantification (LOQ) were calculated from calculating standard 4 
deviation (SD) of 10 operational blank samples as LOD = 3.25 (Students t-test, df=9, 99%CI) × 5 
SD and LOQ = 2.5 × LOD. Elemental composition of ultrapure water (n=6), tap water (n=6) or 6 
PrismaSol filtration fluid (n=18) was determined by ICP-MS. Percentage recovery is mean 7 
recovery from 12 independent runs. Aluminium, Arsenic, Beryllium, Cadmium, Cobalt, Lead, 8 
Nickel, Silver, Titanium, Thallium and Uranium were measurable above LOD in plasma, but not 9 
in effluent. As these elements were not a focus of our hypotheses, values are not reported. Barium 10 
and Boron were quantifiable but were not included in the NIST CRM and are therefore also not 11 
reported. 12 
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Figures 1 
Figure 1. Plasma amino acids and effluent loss during different modes of RRT 2 
 3 
Figure 1. Plasma amino acids and their loss in effluent during different modes of RRT. 4 
Plasma (A,C,E) and effluent (B,D,F) were sampled prior to, at the end, and 1-2h after the end of 5 
each RRT session. Alpha amino acids (x20 standard proteogenic plus a further 18 amino acids) 6 
were measured after deproteinisation and derivatisation using a Biochrom 20 (Biochrom, 7 
Cambridge, UK). Data (means ±S.E.) are presented corrected (i.e. included as co-variates in the 8 
statistical model) for dose-of-dialysis (urea reduction ratio for plasma levels; solute removal index 9 
for effluent losses) and plasma concentration (for calculation of effluent losses only). If necessary, 10 
to normalise residual error before statistical analysis, data were log10 transformed. Graphs were 11 
generated in Graphpad Prism 6 (Graphpad Software Inc, Ca, USA). Analysis was by RM-ANOVA 12 
or mixed effect models, as appropriate, with RRT mode and time as fixed effects and patientID 13 
as a nested random effect, using Genstat v18 (VSNi, Rothampsted, UK). Statistical significance 14 
was accepted at P<0.05.  15 
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Figure 2. Plasma trace elements during different modes of RRT 1 
 2 
Figure 2. Plasma trace elements during RRT. Plasma was sampled prior to, during, at the end 3 
and 1-2h after each RRT session for measurement of trace elements.  Data (means ±S.E.) in 4 
plasma are presented corrected (i.e. included as a co-variate) for dose-of-dialysis (urea reduction 5 
ratio). If necessary, to normalise residual error before statistical analysis, data were log10 6 
transformed. Statistical analysis was by RM-ANOVA or mixed effect models, as appropriate, with 7 
RRT mode and time as fixed effects and patient ID as a nested random effect, using Genstat v18 8 
(VSNi, Rothampsted, UK). Statistical significance was accepted at P0.002 (adjusted for the 9 
number of comparisons). Fig 1A is sum of all measurable trace elements >LOQ (Cs, Cr, Cu, Fe, 10 
Li, Mn, Mo, Rb, Se, Sr, V, Zn).  11 
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Figure 3. Effluent trace elements during different modes of RRT. 1 
 2 
Figure 3. Effluent trace elements during different modes of RRT. A-D; Concentrations of trace elements 3 
were measured in spot samples of post-filter baseline effluent after ‘priming’ of each RRT machine 4 
before patient was connected (‘BASE’) or at the end of each session (‘END’). Total losses were 5 
estimated by multiplying measured concentrations in BASE or END sample (µgs/L) by the total 6 
volume in liters of effluent produced for each patient for that session. Data are estimated mean 7 
after correction (i.e. included as co-variates in the statistical model) for dose-of-dialysis (solute 8 
removal index) and plasma concentration. If necessary, to normalise residual error before analysis, 9 
data were log10 transformed. Analysis was by RM-ANOVA or mixed effect models, as appropriate, 10 
with RRT mode and time as fixed effects and patient ID as a nested random effect, using Genstat 11 
v18 (VSNi, Rothampsted, UK). Estimated effect size was calculated by the statistical package with 12 
IHD as referent category for the effects of mode and time (as indicated on eacg graph). Statistical 13 
significance was accepted at P0.003 (adjusted for the number of comparisons). E; Table, 14 
Potassium included for orientation of RRT effects, as it is known that SLED-F removes more K+ than 15 
IHD. *data for above graphs also included on table for comparison to other trace 16 
elements.**Barium levels were quantifiable but since values are not included in the CRM 17 
(Seronorm L2 Urine) data should be interpreted with caution.   18 
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Figure 4. Comparison of plasma amino acids and trace elements between first and second RRT 1 
session 2 
 3 
Figure 4. Plasma amino acids and trace elements during the first (RRT1) and second (RRT2) session of 4 
renal replacement therapy. Plasma was sampled before, mid-way through and at the end of each RRT 5 
session. Micronutrients were measured in spot samples of plasma as described in Methods.  Data (means 6 
±S.E.) are presented corrected (i.e. included as co-variates in the statistical model) for dose-of-dialysis 7 
(urea reduction ratio). If necessary, to normalise residual error before statistical analysis, data were log10 8 
transformed. Graphs were generated in Graphpad Prism 6 (Graphpad Software Inc, Ca, USA). Analysis was 9 
by RM-ANOVA or mixed effect models (Genstat v18; VSNi, Rothampsted, UK), as appropriate, with RRT 10 
mode, time and session as fixed effects. Patient ID was included as a nested random effect. Statistical 11 
significance was accepted at P0.002 (adjusted for the number of comparisons).   12 
- 6 - 
 
Figure 5. Comparison of effluent amino acid and trace element loss between first and second 1 
RRT 2 
 3 
Figure 5. Comparison of effluent amino acid and trace element loss during the first (RRT1) and second 4 
(RRT2) session of renal replacement therapy. Effluent was sampled before, mid-way through and at the 5 
end of each RRT session. Concentrations of micronutrients were measured in spot samples of baseline 6 
effluent (i.e. after ‘priming’ each dialyser; IHD, SLED-F) or in replacement solution (e.g. PrismaSol for 7 
CVVH). Total losses were estimated by multiplying all measured concentrations (µgs/L) by the total 8 
volume of effluent produced for each patient. Data (means ±S.E.) are presented corrected (i.e. included 9 
as co-variates in the statistical model) for dose-of-dialysis (urea reduction ratio for plasma levels; solute 10 
removal index for effluent losses) and plasma concentration (for calculation of effluent losses only). If 11 
necessary, data were log10 transformed before statistical analysis to normalise residual error. Graphs 12 
were generated in Graphpad Prism 6 (Graphpad Software Inc, Ca, USA). Analysis was by RM-ANOVA or 13 
mixed effect models (Genstat v18; VSNi, Rothampsted, UK), as appropriate, with RRT mode, time and 14 
session as fixed effects. PatientID was included as a nested random effect. Statistical significance was 15 
accepted at P0.002 (adjusted for the number of comparisons).  16 
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Figure 6. Reference diagram 1 
 2 
 3 
